BRIEF-AstraZeneca Sees FY Core EPS To Increase By Low Double-Digit To Low Teens Pct

AstraZeneca PLC: * FINAL RESULTS

* QTRLY CORE EPS $1.45 * FY CORE EPS IS EXPECTED TO INCREASE BY A LOW DOUBLE-DIGIT TO LOW TEENS PERCENTAGE

* FY TOTAL REVENUE IS EXPECTED TO INCREASE BY A LOW DOUBLE-DIGIT TO LOW TEENS PERCENTAGE * QTRLY TOTAL REVENUE $12,024 MILLION VERSUS $11,207 MILLION REPORTED YEAR AGO

* SECOND INTERIM DIVIDEND DECLARED OF $1.97 PER SHARE, MAKING A TOTAL DIVIDEND DECLARED FOR FY 2023 OF $2.90 PER SHARE * FY OTHER OPERATING INCOME IS EXPECTED TO DECREASE SUBSTANTIALLY

* FY COLLABORATION REVENUE IS EXPECTED TO INCREASE SUBSTANTIALLY, DRIVEN BY SUCCESS-BASED MILESTONES AND CERTAIN ANTICIPATED TRANSACTIONS * ANTICIPATED BOTH FY 2024 TOTAL REVENUE AND CORE EPS WOULD INCUR A LOW SINGLE-DIGIT ADVERSE IMPACT FROM FX RATES VERSUS PERFORMANCE AT CER

* FY EXCLUDING COVID-19 MEDICINES, TOTAL REVENUE INCREASED 15% AND PRODUCT SALES INCREASED 14% * CAPITAL EXPENDITURE IS EXPECTED TO INCREASE SUBSTANTIALLY IN 2024 Source text for Eikon: Further company coverage: